New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients